{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:39:06Z","timestamp":1777959546996,"version":"3.51.4"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"3334","license":[{"start":{"date-parts":[[2011,8,15]],"date-time":"2011-08-15T00:00:00Z","timestamp":1313366400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>AIM OF STUDY: To  compare rates of treatment interruption because of side effects and completion rates between subjects treated for latent  tuberculosis infection (LTBI) by isoniazid (INH) for 6 months and subjects  treated with rifampicin (RIF) for 4\u00a0months.\n        METHODS: Retrospective analysis of all patients treated for LTBI by INH  (1993\u20132002) or RIF (2004\u20132007) based on a database including age, gender, prior  liver diseases, alcohol consumption, completion rates, time and cause of  interruption and monthly analysis of ASAT and ALAT.\n        RESULTS: 624 subjects were included, 426 treated by INH and 198 by RIF.  Gender, origin, history of prior hepatic disease and alcohol excess did not  differ between groups. Treatment interruption because of hepatotoxicity was  significantly higher in the INH group than in the RIF group (6.1% vs 2.0%; p = 0.03).  Completion of treatment was significantly higher in the RIF group compared to  the INH group (83% vs 74%; p = 0.02).\n        CONCLUSION: A 4-month RIF treatment was associated with significantly  less interruption of treatment because of hepatotoxicity and higher completion  rates compared to a 6-month INH regimen. These results support the RIF regimen  as an alternative to the presently recommended 9 months of INH in clinical  practice.<\/jats:p>","DOI":"10.4414\/smw.2011.13240","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T18:31:28Z","timestamp":1320345088000},"page":"w13240","source":"Crossref","is-referenced-by-count":6,"title":["Adverse  effects and adherence to treatment of rifampicin 4\u00a0months vs isoniazid 6\u00a0months  for latent tuberculosis"],"prefix":"10.57187","volume":"141","author":[{"given":"I","family":"Fr\u00e9sard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PO","family":"Bridevaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JP","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36756","published-online":{"date-parts":[[2011,8,15]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1333\/1550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1333\/1551","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/1333\/1550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T03:05:23Z","timestamp":1755227123000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/1333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,15]]},"references-count":0,"journal-issue":{"issue":"3334","published-online":{"date-parts":[[2011,8,15]]}},"URL":"https:\/\/doi.org\/10.4414\/smw.2011.13240","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,15]]}}}